Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00331643 · ClinicalTrials.gov registry record · Phase 2
Ixabepilone in Treating Young Patients With Refractory Solid Tumors
A Phase 2 study of Recurrent Adult Soft Tissue Sarcoma and Recurrent Childhood Rhabdomyosarcoma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT00331643 is a Phase 2 study of Recurrent Adult Soft Tissue Sarcoma and Recurrent Childhood Rhabdomyosarcoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 120 participants, above the 78-participant average among 11 other Recurrent Adult Soft Tissue Sarcoma trials with a reported enrollment target (54% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00331643, a Phase 2 study of Recurrent Adult Soft Tissue Sarcoma and Recurrent Childhood Rhabdomyosarcoma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial is studying how well ixabepilone works in treating young patients with refractory solid tumors. Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Conditions Studied
Interventions
- DRUG ixabepilone
Study Locations (1)
California
- Children's Oncology Group - Arcadia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2006-04 |
| Est. Completion | 2009-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00331643
The ClinicalTrials.gov registry entry for NCT00331643 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 78-participant average among 11 other Recurrent Adult Soft Tissue Sarcoma trials with a reported enrollment target (54% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Recurrent Adult Soft Tissue Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which ixabepilone is the first listed.
NCT00331643 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00331643 about?
NCT00331643 is a clinical study titled "Ixabepilone in Treating Young Patients With Refractory Solid Tumors". This phase II trial is studying how well ixabepilone works in treating young patients with refractory solid tumors. Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
What is the current status of trial NCT00331643?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2006-04. Estimated completion is 2009-06.
What conditions does trial NCT00331643 study?
This clinical trial studies the following conditions: Recurrent Adult Soft Tissue Sarcoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Adult Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma.
What interventions are being tested in trial NCT00331643?
The interventions under investigation include: ixabepilone (DRUG).
Who is sponsoring clinical trial NCT00331643?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00331643 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Adult Soft Tissue Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Vorinostat and Bortezomib in Treating Patients With Advanced Soft Tissue Sarcoma
COMPLETED · Phase 2
-
Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery
COMPLETED · Phase 2
-
Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma
COMPLETED · Phase 2
-
Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma
COMPLETED · Phase 2
-
CCI-779 in Treating Patients With Soft Tissue Sarcoma or Gastrointestinal Stromal Tumor
COMPLETED · Phase 2
-
A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas
COMPLETED · Phase 2
Explore more on PlainTrial
Recurrent Adult Soft Tissue Sarcoma
All registered trials for this condition
Recurrent Childhood Rhabdomyosarcoma
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.